

**DESCRIPTION**

<b>Species Reactivity</b>	Mouse
<b>Specificity</b>	Detects mouse Lymphotoxin- $\alpha$ /TNF- $\beta$ in Western blots. In Western blots, approximately 5% cross-reactivity with recombinant human Lymphotoxin- $\alpha$ /TNF- $\beta$ is observed (non-reducing conditions).
<b>Source</b>	Polyclonal Goat IgG
<b>Purification</b>	Antigen Affinity-purified
<b>Immunogen</b>	<i>E. coli</i> -derived recombinant mouse Lymphotoxin- $\alpha$ /TNF- $\beta$
<b>Formulation</b>	Lyophilized from a 0.2 $\mu$ m filtered solution in PBS with BSA as a carrier protein. See Certificate of Analysis for details.

**APPLICATIONS**

**Please Note:** Optimal dilutions should be determined by each laboratory for each application. *General Protocols* are available in the Technical Information section on our website.

	<b>Recommended Concentration</b>	<b>Sample</b>
<b>Western Blot</b>	0.1 $\mu$ g/mL	Recombinant Mouse Lymphotoxin- $\alpha$ /TNF- $\beta$
<b>Immunohistochemistry</b>	5-15 $\mu$ g/mL	Perfusion fixed frozen sections of mouse thymus

**PREPARATION AND STORAGE**

<b>Reconstitution</b>	Reconstitute at 0.2 mg/mL in sterile PBS.
<b>Shipping</b>	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
<b>Stability &amp; Storage</b>	<b>Use a manual defrost freezer and avoid repeated freeze-thaw cycles.</b> <ul style="list-style-type: none"> <li>● 12 months from date of receipt, -20 to -70 °C as supplied.</li> <li>● 1 month, 2 to 8 °C under sterile conditions after reconstitution.</li> <li>● 6 months, -20 to -70 °C under sterile conditions after reconstitution.</li> </ul>

**BACKGROUND**

Tumor necrosis factor-beta (TNF- $\beta$ ), also known as lymphotoxin-alpha (LT- $\alpha$ ), is a secreted homotrimeric glycoprotein belonging to the TNF superfamily and is designated TNFSF1B. It is produced by NK, T, and B cells. TNF- $\beta$  was originally identified as protein that kills tumor cells in cell culture supernatants of a lymphoblastoid cell line. The TNF- $\beta$  subunit also associates with the type II transmembrane TNF superfamily protein lymphotoxin beta (LT $\beta$ ) to generate two types of heterotrimers designated as LT $\alpha$ 1 $\beta$ 2 (a single TNF- $\beta$  chain non-covalently associated with two chains of LT $\beta$ ), and LT $\alpha$ 2 $\beta$ 1 (1, 2). TNF- $\alpha$ , TNF- $\beta$ , and LT $\beta$  form a subfamily of the TNF related ligands. Their genes are genetically linked within a compact cluster inside the major histocompatibility complex locus (2, 3). The soluble TNF- $\beta$  binds and signals through TNF R1 and TNF R2. In contrast, the membrane-bound LT $\alpha$ 1 $\beta$ 2 interacts specifically with the LT $\beta$  receptor (LT $\beta$ R), which does not bind TNF- $\beta$  or TNF- $\alpha$ . Both TNFR1 and TNFR2 bind LT $\alpha$ 2 $\beta$ 1, which is recognized weakly by LT $\beta$  R (4, 5). TNF R1 and 2 express very broadly, while expression of LT $\beta$  R is restricted to stromal cells of lymphoid tissues. Herpesvirus entry mediator binds TNF- $\beta$  in vitro (6). The physiological importance of such interaction, if it occurs *in vivo*, is unclear. Distinct functions attributed to TNF- $\beta$  from transgenic knock-out mice include, loss of lymph node development, change in splenic architecture, impaired germinal center formation, and susceptibility to pulmonary tuberculosis (7, 8). TNF- $\beta$  also has overlapping physiological functions with LT $\beta$  and TNF- $\alpha$  in lymphoid organogenesis (7). Mouse and human TNF- $\beta$  share approximately 74% homology in their amino acid sequence.

**References:**

1. Aggarwal, B.B. (2003) *Nature Rev. Immunol.* **3**:745.
2. Browning , J.L. et al. (1993) *Cell* **72**:846.
3. Browning, J.L. et al. (1995) *J. Immunol.* **154**:33.
4. Pokholok, D.K. et al. (1995) *Proc. Natl. Acad. Sci. USA* **92**:674.
5. Aggarwal, B.B. et al. (1985) *Nature* **318**:665.
6. Crowe, P.D. et al. (1994) *Science* **264**:707.
7. Mauri, D.N. et al. (1998) *Immunity* **8**:21.
8. Tumanov, A.V. et al. (2003) *Cytokine & Growth Factor Rev.* **14**:275.
9. Roach, D.R. et al. (2001) *J. Exp. Med.* **193**:239.